https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2017-00905
Study of Magrolimab (Hu5F9-G4) in Combination With Cetuximab in Participants With Solid Tumors and...
Study of Magrolimab (Hu5F9-G4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer
https://stanfordhealthcare.org/trials/p/NCT02216409.html
Phase 1 Trial of Hu5F9-G4, a CD47-targeting Antibody
Stanford Health Care delivers the highest levels of care and compassion. SHC treats cancer, heart disease, brain disorders, primary care issues, and many more.
phasetrialtargetingantibody